Injective (INJ) is currently priced at $3.58, reflecting a minor 24-hour change of -0.63%. The asset has seen a daily trading range of $3.52 to $3.65, indicating relatively stable price action in the short term, with a volume of approximately 49.46 million, which represents 13.84% of its market cap.

Technical indicators show that the short-term moving averages (8 SMA at $3.60 and 13 SMA at $3.61) are slightly declining, suggesting a potential bearish sentiment. However, the 21 SMA is flat at $3.58, and the longer-term 144 SMA is up by 2.01% at $3.51, indicating some bullish potential in the mid-term.

The Relative Strength Index (RSI) readings provide further insight; the 1-hour RSI is at 55, showing neutral momentum, while the 7-day RSI at 53 indicates a balance between buying and selling pressures. Price changes over various periods suggest positive momentum, with 30-day price change at approximately 28%, signaling strong upward movement recently.

Fundamentally, INJ remains significantly below its all-time high of $52.62 reached on March 14, 2024, indicating considerable upside potential if market conditions improve. The current price levels and recent price action suggest that market participants are cautiously optimistic about INJ's future, especially given the recent price increases over the past month.

Considering the technical indicators, RSI levels, and the overall market context, the outlook for Injective (INJ) suggests a Buy rating. The asset's relatively low price compared to its all-time high, coupled with strong short-term and medium-term price gains, supports this bullish stance.